Amgen Reveals Positive Phase III Data For Platelet Drug Romiplostim
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong efficacy findings should aid company’s race with GSK to get chronic ITP treatment to market.
You may also be interested in...
Amgen’s Platelet Booster Faces FDA Panel
Risk management plan is likely focus of March 12 ODAC meeting.
Amgen’s Platelet Booster Faces FDA Panel
Risk management plan is likely focus of March 12 ODAC meeting.
Amgen’s March Madness: ESAs, Nplate To Get FDA Advisory Panel Review
Schering’s PegIntron in melanoma will also be reviewed at March 12-13 meeting of FDA’s Oncologic Drugs Advisory Committee.